Monday Lectures
Monday, April 17, 2017 3:45 p.m.
Carson Family Auditorium
Vincent A. Fischetti, Ph.D.
Professor and Head,
Laboratory of Bacterial Pathogenesis and Immunology
The Rockefeller University
Exploiting phage evolution for the development of novel therapeutics
Recommended Readings:
David Bautz. March 20th 2017. CFRX: Phase 2 Trial of CF-301 to Initiate in mid-2017.
Czaplewski, Lloyd; Bax, Richard; Clokie, Martha; et al. (2016). Alternatives to antibiotics-a pipeline portfolio review. LANCET INFECTIOUS DISEASES. 16(2): 239-251
Diez-Martinez, Roberto; De Paz, Hector D.; Garcia-Fernandez, Esther; et al. (2015). A novel chimeric phage lysin with high in vitro and in vivo bactericidal activity against Streptococcus pneumoniae. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 70(6): 1763-1773
Bikard, David; Euler, Chad W.; Jiang, Wenyan; et al. (2014). Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. NATURE BIOTECHNOLOGY. 32(11): 1146-1150
Schuch, Raymond; Lee, Han M.; Schneider, Brent C.; et al. (2014). Combination Therapy With Lysin CF-301 and Antibiotic Is Superior to Antibiotic Alone for Treating Methicillin-Resistant Staphylococcus aureus-Induced Murine Bacteremia. JOURNAL OF INFECTIOUS DISEASES. 209(9): 1469-1478
Pastagia, Mina; Schuch, Raymond; Fischetti, Vincent A.; et al. (2013). Lysins: the arrival of pathogen-directed anti-infectives. JOURNAL OF MEDICAL MICROBIOLOGY. 62:1506-1516
Gilmer, Daniel B.; Schmitz, Jonathan E.; Euler, Chad W.; et al. (2013). Novel Bacteriophage Lysin with Broad Lytic Activity Protects against Mixed Infection by Streptococcus pyogenes and Methicillin-Resistant Staphylococcus aureus. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 57(6): 2743-2750
